
NNMXD
Healthcare · Medical Devices · $14.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 22, 2021 | Time not confirmed | — | -0.47 | — |
| Aug 12, 2021 | Time not confirmed | — | -0.68 | — |
| May 18, 2021 | Time not confirmed | — | -3.52 | — |
| Mar 3, 2021 | Time not confirmed | — | -0.55 | — |
| Nov 23, 2020 | Time not confirmed | — | -0.29 | — |
| Aug 13, 2020 | Time not confirmed | — | -0.37 | — |
| May 19, 2020 | Time not confirmed | — | -0.20 | — |
| Feb 26, 2020 | Time not confirmed | — | -3.36 | — |
| Nov 25, 2019 | Time not confirmed | — | -0.47 | — |
| Aug 15, 2019 | Time not confirmed | — | -0.44 | — |
| May 14, 2019 | Time not confirmed | — | -1.48 | — |
| Feb 27, 2019 | Time not confirmed | — | -2.34 | — |
| Nov 19, 2018 | Time not confirmed | — | 1.21 | — |
| Aug 16, 2018 |
Boston Therapeutics, Inc. develops, manufactures, and commercializes therapeutic drugs to address unmet medical needs in diabetes and inflammatory diseases. The company develops BTI-320, a non-systemic carbohydrate-based compound tablet that is in Phase II clinical trial for reduction of post-meal blood glucose levels in pre-diabetes patients and type 2 diabetes patients; and IPOXYN, an injectable drug to prevent…
| Time not confirmed |
| — |
| -0.21 |
| — |
| May 24, 2018 | Time not confirmed | — | -5.80 | — |
| Mar 27, 2018 | Before the open | — | -0.04 | — |